Compounders sue FDA again over declaring end of shortage for Novo's semaglutide
Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight. | Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight.
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
Semaglutide — the type 2 diabetes and weight loss medication sold under the brand names Ozempic and Wegovy — can expire. If ...
Scientists in China have found a new potential drug target for weight loss. Blocking a protein called CD44 has been shown to ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout newsletter.
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...
Semaglutide use in patients with Type 2 diabetes was associated with reduced postoperative complications after 90 days, according to a study in the March 2025 i ...
2don MSN
With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback